8-K: Tenax Secures Key European Patent for PH-HFpEF Drug

Tenax Therapeutics announced the European Patent Office's intention to grant a patent for TNX-103 (oral levosimendan) for pulmonary hypertension with heart failure with preserved ejection fraction, extending protection in Europe through at least 2040.

Summary

• The European Patent Office (EPO) has notified Tenax Therapeutics of its Intention to Grant a patent for TNX-103 (oral levosimendan) and other formulations of levosimendan, as well as its active metabolites, for use in pulmonary hypertension resulting from heart failure with preserved ejection fraction (PH-HFpEF).
• Once granted, this patent will provide intellectual property protection in Europe through at least December 2040, with potential for an additional European patent term beyond 2040 through supplementary protection certificates (SPCs).
• The patent's claims cover the use of levosimendan when delivered through various routes of administration (oral, intravenous, inhaled, transdermal, and subcutaneous) to treat PH-HFpEF.
• It also includes similar protection for the use of active metabolites of levosimendan (OR1896 and OR1855) and expressly provides protection for a wide range of levosimendan doses, as well as its use in combination with various cardiovascular drugs in PH-HFpEF.
• PH-HFpEF is identified as the most prevalent form of pulmonary hypertension globally, for which no product has been approved to date, representing a significant commercial opportunity for Tenax Therapeutics.
• The company expects to initiate its second registrational Phase 3 study, LEVEL-2, in Europe this year, which will recruit patients across Europe.

Sentiment

Score: 8

Explanation: The intention to grant a broad European patent for a key drug candidate (TNX-103) in a large, unmet medical need (PH-HFpEF) is a significant positive development. It strengthens the company's intellectual property, extends market exclusivity, and supports upcoming clinical trials, indicating strong progress and future commercial potential.

Positives

• Securing an Intention to Grant a patent from the European Patent Office provides significant intellectual property protection for TNX-103 in the European market.
• The patent extends protection through at least December 2040, with potential for further extension via supplementary protection certificates, ensuring a long period of market exclusivity.
• The broad scope of the patent covers various formulations, routes of administration, active metabolites, a wide range of doses, and combination therapies, enhancing the commercial value of TNX-103.
• This European patent strengthens the global IP portfolio, building on existing patents already issued in the U.S. and Canada.
• The timing of this patent is particularly beneficial as the company prepares to initiate its second registrational Phase 3 study (LEVEL-2) in Europe this year, which will recruit patients across the continent.
• TNX-103 targets PH-HFpEF, a prevalent form of pulmonary hypertension with no currently approved treatments, representing a substantial unmet medical need and commercial opportunity.

Risks

• Intellectual property risks, including challenges to patent validity or enforceability.
• Risks associated with clinical trials, including potential for delays, increased costs, design issues, difficulties in site selection or patient enrollment, and unfavorable results.
• Delays in regulatory review and approval processes for product candidates in development.
• Risks related to business strategy, including the prioritization and development of product candidates.
• Uncertainty regarding estimates of the potential market opportunity for product candidates.
• Reliance on third parties, including Orion Corporation, manufacturers, and Contract Research Organizations (CROs).
• Risks concerning the formulation, production, marketing, customer acceptance, and clinical utility of product candidates.
• Competitive position risks within the pharmaceutical industry.
• Challenges in maintaining company culture and recruiting, integrating, and retaining qualified personnel and advisors.
• Risks associated with the company's cash needs and ability to secure future funding.
• Volatility and uncertainty in the global economy and financial markets, including impacts from tariffs, pandemics, global financial and geopolitical uncertainties (e.g., Middle East, Russia-Ukraine conflict).
• Changes in legal, regulatory, and legislative environments in operating markets and their impact on obtaining regulatory approval for products.

Future Outlook

The company expects to initiate its second registrational Phase 3 study, LEVEL-2, in Europe this year, which is an essential step for advancing TNX-103 toward regulatory approval in PH-HFpEF and including global patients in Phase 3 development. The newly granted European patent will provide intellectual property protection through at least December 2040, with potential for further extension, securing a long commercial runway for the drug.

Management Comments

• "This patent protects an important commercial opportunity for Tenax. It builds on multiple patents already issued in the U.S. and Canada, as we continue to strengthen the global IP portfolio of our novel and potentially first-in-disease drug." Chris Giordano, President and Chief Executive Officer of Tenax Therapeutics.
• "The European patent is particularly timely for the Company as we prepare to initiate our second registrational Phase 3 study, LEVEL-2, which will recruit patients across Europe. We expect to initiate LEVEL-2 this year, an essential step not only in advancing TNX-103 toward regulatory approval in PH-HFpEF, but also to including patients from around the world at the Phase 3 stage of development." Chris Giordano, President and Chief Executive Officer of Tenax Therapeutics.

Industry Context

The announcement positions Tenax Therapeutics to address a significant unmet medical need in the cardiopulmonary therapy market, specifically for PH-HFpEF, which currently lacks approved treatments. Securing broad intellectual property protection in Europe, a major pharmaceutical market, enhances the company's competitive stance against potential future entrants and strengthens its global market potential for TNX-103. This move aligns with broader industry trends of pharmaceutical companies seeking to extend patent life and secure market exclusivity for novel therapies addressing prevalent chronic conditions.

Stakeholder Impact

• Shareholders: Positive impact due to strengthened intellectual property, extended market exclusivity, and enhanced commercial potential for a key drug candidate, potentially increasing long-term value.
• Patients (PH-HFpEF): Potential for a novel, first-in-disease treatment to become available in Europe, addressing a significant unmet medical need.
• Employees: Positive impact from company progress and strengthened market position, potentially leading to increased stability and growth opportunities.
• Competitors: Increased barrier to entry for competing therapies targeting PH-HFpEF in Europe due to Tenax's patent protection.

Next Steps

• Formal granting of the European patent for levosimendan in PH-HFpEF.
• Initiation of the LEVEL-2 registrational Phase 3 study in Europe this year.
• Advancing TNX-103 toward regulatory approval in PH-HFpEF.
• Potentially qualifying for European patent supplementary protection certificates (SPCs) to extend patent protection beyond 2040.

Key Dates

Recommendation

The intention to grant a broad European patent for TNX-103 in PH-HFpEF is a significant de-risking event and a strong positive catalyst. It secures long-term market exclusivity in a major market for a drug targeting a large, unmet medical need with no approved treatments. This strengthens the company's competitive position and commercial opportunity, especially as it prepares to initiate a pivotal Phase 3 study in Europe. The extended IP protection through at least 2040 provides a clear runway for potential future revenues, making the stock an attractive 'buy' for long-term growth.

Keywords

Tenax Therapeutics, TENX, Levosimendan, TNX-103, PH-HFpEF, Pulmonary Hypertension, Heart Failure, Patent, European Patent Office, EPO, Cardiopulmonary Therapies, Phase 3 Clinical Trial, LEVEL-2 Study, Drug Development, Intellectual Property